Luye Pharma Group Ltd. (LYPHF)
Luye Pharma Statistics
Share Statistics
Luye Pharma has 3.76B shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 3.76B |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.95B |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 21.27 and the forward PE ratio is null. Luye Pharma's PEG ratio is -1.21.
| PE Ratio | 21.27 |
| Forward PE | n/a |
| PS Ratio | 1.84 |
| Forward PS | n/a |
| PB Ratio | 0.9 |
| P/FCF Ratio | 26.34 |
| PEG Ratio | -1.21 |
Enterprise Valuation
Luye Pharma has an Enterprise Value (EV) of 16.52B.
| EV / Sales | 2.69 |
| EV / EBITDA | 7.95 |
| EV / EBIT | 10.35 |
| EV / FCF | 38.39 |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.32 |
| Quick Ratio | 1.21 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 4.06 |
| Debt / FCF | 19.58 |
| Interest Coverage | 1.52 |
Financial Efficiency
Return on Equity is 4.25% and Return on Invested Capital is 3.51%.
| Return on Equity | 4.25% |
| Return on Assets | 2.09% |
| Return on Invested Capital | 3.51% |
| Revenue Per Employee | $1.17M |
| Profits Per Employee | $101.76K |
| Employee Count | 5,234 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 2.34 |
Taxes
| Income Tax | 161.02M |
| Effective Tax Rate | 23% |
Stock Price Statistics
The stock price has increased by -30.1% in the last 52 weeks. The beta is 1.23, so Luye Pharma's price volatility has been higher than the market average.
| Beta | 1.23 |
| 52-Week Price Change | -30.1% |
| 50-Day Moving Average | 0.3 |
| 200-Day Moving Average | 0.38 |
| Relative Strength Index (RSI) | 26.06 |
| Average Volume (20 Days) | 62 |
Income Statement
In the last 12 months, Luye Pharma had revenue of 6.14B and earned 532.61M in profits. Earnings per share was 0.14.
| Revenue | 6.14B |
| Gross Profit | 4.2B |
| Operating Income | 1.03B |
| Net Income | 532.61M |
| EBITDA | 2.08B |
| EBIT | 1.38B |
| Earnings Per Share (EPS) | 0.14 |
Balance Sheet
The company has 3.24B in cash and 8.42B in debt, giving a net cash position of -5.18B.
| Cash & Cash Equivalents | 3.24B |
| Total Debt | 8.42B |
| Net Cash | -5.18B |
| Retained Earnings | 7.38B |
| Total Assets | 27.2B |
| Working Capital | 2.76B |
Cash Flow
In the last 12 months, operating cash flow was 1.6B and capital expenditures -1.17B, giving a free cash flow of 430.23M.
| Operating Cash Flow | 1.6B |
| Capital Expenditures | -1.17B |
| Free Cash Flow | 430.23M |
| FCF Per Share | 0.12 |
Margins
Gross margin is 68.44%, with operating and profit margins of 16.75% and 8.67%.
| Gross Margin | 68.44% |
| Operating Margin | 16.75% |
| Pretax Margin | 11.4% |
| Profit Margin | 8.67% |
| EBITDA Margin | 33.82% |
| EBIT Margin | 16.75% |
| FCF Margin | 7% |
Dividends & Yields
LYPHF pays an annual dividend of $0.02, which amounts to a dividend yield of 2.17%.
| Dividend Per Share | $0.02 |
| Dividend Yield | 2.17% |
| Dividend Growth (YoY) | -6.78% |
| Payout Ratio | 81.44% |
| Earnings Yield | 4.7% |
| FCF Yield | 3.8% |
Analyst Forecast
Currently there are no analyst rating for LYPHF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 1.24 |
| Piotroski F-Score | 5 |